Axsome Therapeutics, Inc.·4

Mar 6, 6:12 PM ET

Saad Mark E 4

4 · Axsome Therapeutics, Inc. · Filed Mar 6, 2023

Insider Transaction Report

Form 4
Period: 2023-03-02
Saad Mark E
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-03-02+2,2242,224 total
    Exercise: $65.32From: 2023-03-02Exp: 2033-03-01Common Stock (2,224 underlying)
Footnotes (1)
  • [F1]Represents 2,224 options elected to be received in lieu of cash compensation earned in 2022. All of such options are immediately exercisable.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION